These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 15126788)

  • 1. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
    Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
    Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
    Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
    Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
    Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF; Regan MM; Olumi AF; DeWolf WC
    J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
    Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
    J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database.
    Freedland SJ; Presti JC; Amling CL; Kane CJ; Aronson WJ; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):736-41. PubMed ID: 12670557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.